In some "good news" for scientists working on a viable vaccine for COVID-19, a latest study has found that the SARS-CoV-2 virus behind the disease shows little variability, despite having at least six strains.
Published in the journal Frontiers in Microbiology, the "most extensive" study ever carried out on SARS-CoV-2 sequencing drew from the analysis of 48,635 coronavirus genomes, which were isolated by researchers in labs all over the world.
The researchers at the University of Bologna in Italy mapped the spread and the mutations of the virus during its journey to all continents.
The findings show that the novel coronavirus presents little variability, approximately seven mutations per sample.
Common influenza has a variability rate that is more than double, the researchers said.
"The SARS-CoV-2 coronavirus is presumably already optimised to affect human beings, and this explains its low evolutionary change," said Federico Giorgi, a researcher at University of Bologna, and coordinator of the study.
"This means that the treatments we are developing, including a vaccine, might be effective against all the virus strains," Giorgi said.
The researchers noted that currently there are six strains of the novel coronavirus.
The original one is the L strain, that appeared in Wuhan in December 2019. Its first mutation -- the S strain -- appeared at the beginning of 2020, while, since mid-January, we have had strains V and G, they said.
To date strain G is the most widespread: it mutated into strains GR and GH at the end of February, according to the researchers.
"Strain G and its related strains GR and GH are by far the most widespread, representing 74 per cent of all gene sequences we analysed," said Giorgi.
"They present four mutations, two of which are able to change the sequence of the RNA polymerase and Spike proteins of the virus. This characteristic probably facilitates the spread of the virus," he said.
Besides the six main coronavirus strains, researchers identified some infrequent mutations that, they said, are not worrying at the moment but should be monitored.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)